Vaxart (NASDAQ:VXRT) released its earnings results on Sunday. The biotechnology company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.04), Briefing.com reports. Vaxart had a negative net margin of 281.50% and a negative return on equity of 84.90%. The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.62 million. The company’s quarterly revenue was down 82.8% compared to the same quarter last year.
Shares of VXRT stock traded up $0.74 on Tuesday, hitting $8.76. The stock had a trading volume of 70,254,812 shares, compared to its average volume of 19,463,066. The stock’s 50 day moving average is $6.40 and its 200-day moving average is $6.87. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -15.19 and a beta of -0.11. Vaxart has a 52-week low of $2.23 and a 52-week high of $24.90.
Several research firms have commented on VXRT. B. Riley restated a “buy” rating and issued a $13.00 price target (down previously from $16.00) on shares of Vaxart in a report on Thursday, March 4th. Zacks Investment Research cut Vaxart from a “hold” rating to a “sell” rating in a report on Tuesday, March 9th.
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection.
See Also: Understanding the two types of arbitrage
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.